[1]黄金文,黄瑞宏,黄国清.急性髓系白血病患者FLT3检测的临床意义[J].现代检验医学杂志,2016,31(05):110-112.[doi:10.3969/j.issn.1671-7414.2016.05.030]
　HUANG Jin-wen,HUANG Rui-hong,HUANG Guo-qing.Clinical Significance of FLT3 in patients with AML[J].Journal of Modern Laboratory Medicine,2016,31(05):110-112.[doi:10.3969/j.issn.1671-7414.2016.05.030]
点击复制

急性髓系白血病患者FLT3检测的临床意义()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第31卷
期数:
2016年05期
页码:
110-112
栏目:
论著
出版日期:
2016-10-21

文章信息/Info

Title:
Clinical Significance of FLT3 in patients with AML
文章编号:
1671-7414(2016)05-110-03
作者:
黄金文1; 黄瑞宏2; 黄国清3
1.深圳市石岩人民医院检验科,广东深圳 518108;
2.深圳市血液病研究所,广东深圳 518031;
3.深圳市龙华新区中心医院检验科,广东深圳 518110
Author(s):
HUANG Jin-wen1; HUANG Rui-hong2; HUANG Guo-qing3
1.Department of Clinical Laboratory,Shiyan People's Hospitalof Shenzhen, Guangdong Shenzhen 518108,China;
2.the Institute of Hematology DiseasesResearch, Guangdong Shenzhen 518031,China;
3.Department of Clinical Laboratory, Longhua New District
关键词:
fms样酷氨酸激酶;  急性髓细胞白血病;  预后;  总体生存时间;  无病生存时间
分类号:
R551.3; R392.11
DOI:
10.3969/j.issn.1671-7414.2016.05.030
文献标志码:
A
摘要:
目的 探讨fms样酷氨酸激酶3(fms-like tyrosine kinase,FLT3)在急性髓细胞白血病(acute myelocytic leukemia,AML)患者的表达情况及临床意义。方法 用荧光原位杂交法(fluorescence in situ hybrization,FISH)检测80例AML患者(其中核型正常者40例,核型异常者40例)白血病细胞FLT3的表达情况。结果 核型正常的AML FLT3的表达率为5.0%,核型异常的AML FLT3的表达率为30.7%。难治复发的AML FLT3的表达率是43.3%,持续完全缓解的AML FLT3的表达率是4.5%。有FLT3表达的AML患者24个月随访无病生存(disease-free survival,DFS)和总体生存(overall survival,OS)时间分别为65%和86%,而无FLT3表达的AML患者无病生存(DFS)和总体生存(OS)时间分别为20%和40%,二者差异有统计学意义(P<0.05)。结论 FLT3是AML患者预后不好的因素之一,FLT3高表达与白血病的恶性程度正相关。
Abstract:
Objective To explore the expression of FLT3 onthe cells from acute myeloblastic leukemia(AML)and its clinical signficance.Methods The expression of FLT3 from 80 AML cases was measured by FISH.All cases were indentified by karyotyping,40 cases were normal karyotye,and the other 40 cases were abnormal.Results TheFLT3 expression level was different in different AML cases.The expression ratein normal karyotype cases was 5.0%,but in abnormal cases 30.7%,in refractory relapse cases 43.3%,in continual complete remission cases 4.5%.The patients' DFS(Disease-Free survival)and OS(overall survival)without FLT3 expression were 65% and 86% in 24 months' following investigation,but the patients'DFS and OS with FLT3 expression were 20% and 40% respectively.The difference wasdistinct between them(P<0.05).Conclusion FLT3 can be thought as a new marker for worse prognosis of AML patients,and its expression level is associated with maglignacy-grade.

参考文献/References:

[1] Rosnet O,Marchetto S,Delapeyriene O,et al.Murine FLT3,a geneencoding a novel tyrosine kinase receptor of the PDGF-GSF1R family[J].Oncogene,1991,6(9):1641-1650.
[2] Mead AJ,Kharazi S,Atkinson D,et al.FLT3-ITDs instruct a myeloid differentiation and transformation bias in lymphomyeloid multipotent progenitor[J].Cell Rep,2013,3(6):1766-1776.
[3] Molica M,Breccia M.FLT3-ITD in acute promyelocytic leukemia:Clinicaldistinct profile but still controversial prognosis[J].Leuk Res,2015,39(4):397-399.
[4] Kindler T,Lipka DB,Fisher T.FLT3 as a therapeutic target in AML:stillchallenging after all these years[J].Blood,2010,116(24):5089-5102.
[5] Gale RE,Green C,Allen C,et al.The impact of FL T3 internal tandem duplication mutant level,number,size and interaction with NPM1 mutation in a large cohort of young adult patients with acute myeloid leukemia[J].Blood,2008,111(5):2776-2784.
[6] Sharawat SK,Bakhshi R,Vishnubhatla S,et al.High receptor tyrosine kinase(FLT3,KIT)transcript versus anti-apoptotic(BCL2)transcript ratio independently predicts inferior outcome in pediatric acute myeloid leukemia[J].BloodCells Mol Dis,2015,54(1):56-64.
[7] Stone RM,Fischer T,Paquette R,et al.Phase IB stu-dy of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia[J].Leukemia,2012,26(9):2061-2068.
[8] He BL,Shi X,Man CH,et al.Functions of FLT3 in zebrafish hem-atopoiesis and its revelance to human acute myeloid leukemia[J].Blood,2014,123(16):2518-2529.
[9] Leung AY,Man CH,Kwong YL,et al.FLT3 inhibition:a moving and evolvingtarget in acute myeloid leukemia[J].Leukemia,2013,27(2):260-268.
[10] Whitman SP,Ruppert AS,Radmacher MD,et al.FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de no-vo cytogenetically normal acutemyeloid leukemia lacking FLT3 internal tandem duplications[J].Blood,2008,111(3):1552-1559.
[11] 丁子轩,沈宏杰,缪竞诚,等.C-kit,NPM1,FLT3基因突变在656例中国急性髓系白血病患者中的分布及其对预后的影响[J].中华血液学杂志,2012,33(10):829-834. Ding ZX,Shen HJ,Miao JC,et al.C-kit,NPM1 and FLT3 gene mutation patterns and their prognostic significance in 656 Chinese patients with acute myeloid leukemia[J].Chin J Hematol,2012,33(10):829-834.

备注/Memo

备注/Memo:

作者简介:黄金文(1975-)男,硕士,副主任技师,主要从事血液学与分子生物学检验,Tel:18138851543,E-mail:jinwenh567@sina.com.cn。
更新日期/Last Update: 2016-10-30